Summary & Overview
CPT 82043: Quantitative Urine Microalbumin Laboratory Test
CPT code 82043 represents the quantitative measurement of microalbumin in urine, a laboratory test widely used to detect early kidney damage and monitor renal health in patients with risk factors such as diabetes and hypertension. This procedure is performed in independent laboratory settings and is a cornerstone in preventive care for chronic kidney disease. Nationally, the code is recognized by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, ensuring broad coverage for patients across the United States.
This publication provides a comprehensive overview of CPT code 82043, including payer coverage, clinical context, and related billing practices. Readers will gain insight into the importance of urine microalbumin testing, typical sites of service, and how this code fits within broader laboratory and clinical workflows. The summary also highlights associated modifiers and taxonomies, relevant ICD-10 diagnoses, and related CPT codes, offering a clear understanding of the code’s role in laboratory medicine and its impact on patient care. Policy updates and reimbursement benchmarks are discussed to inform stakeholders about current trends and requirements in medical billing for this essential laboratory service.
CPT Code Overview
CPT code 82043 is used to report the quantitative measurement of microalbumin in urine. This laboratory test is essential for detecting and monitoring early signs of kidney disease, particularly in patients at risk due to conditions such as diabetes or hypertension. The service is classified as a laboratory procedure and is typically performed in an independent laboratory setting, designated as Place of Service 81. Quantitative urine microalbumin testing provides clinicians with critical information for assessing renal function and guiding patient management.
Clinical & Coding Specifications
Clinical Context
A patient with a history of diabetes, hypertension, or chronic kidney disease presents to their primary care provider for routine monitoring. The provider orders a quantitative urine microalbumin test (CPT code 82043) to assess for early signs of kidney damage. The urine sample is collected and sent to an independent laboratory (Place of Service 81) for analysis. The laboratory performs the test to measure the amount of albumin in the urine, which helps in detecting microalbuminuria, an early indicator of renal impairment. Results are reported back to the provider, who uses them to guide ongoing management of the patient's underlying condition.
Coding Specifications
-
Modifier
91: Used when the urine microalbumin test (CPT code 82043) is repeated on the same patient to monitor changes over time, such as in chronic disease management. -
Modifier
59: Applied when the urine microalbumin test is performed as a distinct procedural service, separate from other laboratory tests during the same encounter.
| Provider Taxonomy Code | Specialty Description |
|---|---|
291U00000X | Clinical Medical Laboratory |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
These taxonomies represent the clinical laboratory performing the test and the physicians who may order it.
Related Diagnoses
-
R80.9- Proteinuria, unspecified- Indicates the presence of protein in the urine, which is a key reason for ordering a urine microalbumin test.
-
N18.9- Chronic kidney disease, unspecified- Patients with chronic kidney disease require regular monitoring of urine albumin to assess disease progression.
-
E11.9- Type 2 diabetes mellitus without complications- Diabetes is a major risk factor for kidney damage; microalbumin testing is part of routine screening.
-
I10- Essential (primary) hypertension- Hypertension can lead to kidney damage; urine microalbumin testing helps detect early renal involvement.
-
N39.0- Urinary tract infection, site not specified- UTIs may cause transient proteinuria; microalbumin testing can help differentiate persistent proteinuria from infection-related changes.
Related CPT Codes
-
82044- Albumin; urine, microalbumin, semiquantitative- Used for a semiquantitative assessment of urine microalbumin. May be ordered when a less precise measurement is sufficient or as an initial screen.
-
82570- Creatinine; other source- Often performed alongside
82043to calculate the albumin-to-creatinine ratio, which provides a more accurate assessment of kidney function.
- Often performed alongside
-
84156- Protein, total, except by refractometry; other source- Measures total protein in urine or other sources. Can be used to evaluate overall proteinuria in conjunction with microalbumin testing.
-
81001- Urinalysis, automated, with microscopy- Commonly ordered with
82043to provide a comprehensive evaluation of urine, including detection of other abnormalities.
- Commonly ordered with
These codes are frequently used together in clinical workflows for patients at risk of kidney disease or with conditions such as diabetes and hypertension. 82044 may be used as an alternative to 82043 when a quantitative result is not required.
National Reimbursement Benchmarks
For CPT code 82043, the national mean rate for BUCA (average commercial) is $6.54, which is notably higher than the UnitedHealth Group mean rate of $4.79. Among the commercial payers, Cigna has the highest mean rate at $8.59, while UnitedHealth Group is the lowest.
Rate dispersion, measured as the difference between the 75th and 25th percentiles, varies across payers. Cigna exhibits the widest spread at $4.00, indicating greater variability in rates, while Blue Cross Blue Shield shows a tighter range of $2.20. UnitedHealth Group also has a wide dispersion of $3.67, suggesting significant rate variation. The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.